These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6268955)

  • 21. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine.
    Irie H; Harada Y; Kataoka M; Nagamuta M; Moriya Y; Handa M; Saito M; Matsubara S; Kojima K; Sugawara Y
    J Virol; 1992 Apr; 66(4):2428-34. PubMed ID: 1312638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunization of mice with specific HSV-1 glycoproteins.
    Chan WL
    Immunology; 1983 Jun; 49(2):343-52. PubMed ID: 6303950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.
    McKendall RR
    Infect Immun; 1977 May; 16(2):717-9. PubMed ID: 193798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.
    O'Donnell CA; Chan WL
    Clin Exp Immunol; 1991 Oct; 86(1):30-6. PubMed ID: 1655317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2.
    Watari E; Dietzschold B; Szokan G; Heber-Katz E
    J Exp Med; 1987 Feb; 165(2):459-70. PubMed ID: 3029270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed hypersensitivity and immune protection against herpes simplex virus: suppressor T cells that regulate the induction of delayed hypersensitivity effector T cells also regulate the induction of protective T cells.
    Schrier RD; Ishioka GY; Pizer LI; Moorhead JW
    J Immunol; 1985 May; 134(5):2889-93. PubMed ID: 2580006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D.
    Wachsman M; Luo JH; Aurelian L; Paoletti E
    Vaccine; 1992; 10(7):447-54. PubMed ID: 1376951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
    Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of subviral herpes simplex virus type 1 preparation: protection of mice against intradermal challenge with type 1 and type 2 viruses.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1980; 66(3):207-14. PubMed ID: 6255896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live vaccinia virus recombinants expressing herpes simplex virus genes.
    Rooney JF; Wohlenberg CR; Moss B; Notkins AL
    Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Design of inactivated polyvalent antiherpes vaccines].
    Andonov P; Dundarov S; Bakalov B
    Vopr Virusol; 1979; (6):665-71. PubMed ID: 230648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.